Knoll Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Knoll Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.18M	Buy	485,515 +249,562	+106%	+$1.25M	1.21%	21
2025 Q4	$1.24M	Buy	235,953 +173,264	+276%	+$872K	0.57%	27
2025 Q3	$331K	Hold	62,689	–	–	0.18%	36
2025 Q2	$356K	Buy	+62,689	New	+$357K	0.25%	34
2022 Q4	–	Sell	-88,629	Closed	-$269K	–	22
2022 Q3	$269K	Sell	88,629 -1	-0%	-$4	0.16%	28
2022 Q2	$461K	Hold	88,630	–	–	0.26%	31
2022 Q1	$709K	Hold	88,630	–	–	0.45%	23
2021 Q4	$651K	Sell	88,630 -25,761	-23%	-$473K	0.36%	22
2021 Q3	$3.2M	Hold	114,391	–	–	1.6%	9
2021 Q2	$4.46M	Hold	114,391	–	–	2.33%	9
2021 Q1	$5.38M	Hold	114,391	–	–	3.5%	8
2020 Q4	$4.49M	Hold	114,391	–	–	3.06%	6
2020 Q3	$2.92M	Hold	114,391	–	–	2.39%	7
2020 Q2	$8.15M	Hold	114,391	–	–	4.71%	4
2020 Q1	$6.01M	Hold	114,391	–	–	5.64%	4
2019 Q4	$9.35M	Buy	114,391 +20,000	+21%	+$1.41M	6.9%	4
2019 Q3	$5.33M	Hold	94,391	–	–	4.88%	4
2019 Q2	$11.3M	Hold	94,391	–	–	9.23%	3
2019 Q1	$17.4M	Hold	94,391	–	–	13.2%	3
2018 Q4	$16.8M	Hold	94,391	–	–	19.17%	3
2018 Q3	$29.6M	Hold	94,391	–	–	25.05%	2
2018 Q2	$37.8M	Hold	94,391	–	–	32.09%	1
2018 Q1	$33.9M	Hold	94,391	–	–	34.77%	1
2017 Q4	$37.4M	Hold	94,391	–	–	32.97%	1
2017 Q3	$40.2M	Hold	94,391	–	–	34.4%	1
2017 Q2	$15.1M	Hold	94,391	–	–	20.02%	3
2017 Q1	$11.7M	Hold	94,391	–	–	17.7%	2
2016 Q4	$11.4M	Buy	94,391 +40,000	+74%	+$6.26M	20.08%	2
2016 Q3	$8.04M	Hold	54,391	–	–	14.09%	2
2016 Q2	$3.21M	Hold	54,391	–	–	1.04%	7
2016 Q1	$3.48M	Hold	54,391	–	–	1.41%	6
2015 Q4	$4.57M	Hold	54,391	–	–	1.69%	6
2015 Q3	$5.51M	Hold	54,391	–	–	2.34%	5
2015 Q2	$6.88M	Buy	54,391 +45,867	+538%	+$6.89M	2.22%	5
2015 Q1	$669K	Buy	+8,524	New	+$686K	0.19%	12

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Knoll Capital Management's ABEO Position: Q1 2026 in Review

Knoll Capital Management increased its Abeona Therapeutics (ABEO) stake by 106% in Q1 2026, buying an estimated $1.25M and bringing the position to 485,515 shares worth $2.18M. The position accounts for 1.21% of the portfolio, ranked #21.

Knoll Capital Management first reported a position in ABEO in Q1 2015 and has held it in 35 quarters since. The position peaked at $40.2M in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Knoll Capital Management held 485,515 shares of Abeona Therapeutics worth $2.18M as of Q1 2026.
Knoll Capital Management bought 249,562 Abeona Therapeutics shares in Q1 2026, an estimated $1.25M.
Abeona Therapeutics made up 1.21% of Knoll Capital Management's portfolio in Q1 2026, its #21 holding.
Knoll Capital Management first reported a position in Abeona Therapeutics in Q1 2015 and has held it in 35 quarters since.
Knoll Capital Management's Abeona Therapeutics position peaked at $40.2M in Q3 2017.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.